Month: September 2026

EfTEN United Property Fund earned a net profit of 58 thousand euros in August and 624 thousand euros over the first eight months of 2026 (2 012 thousand euros in the same period last year). The net asset value (NAV) of the fund unit was 11.58 euros at the end of August, increasing 0.2% over the month.

The lower-than-usual profit was primarily related to the fund’s investment in the shares of EfTEN Real Estate Fund AS, the price of which fell by 1.8% on the Tallinn Stock Exchange in August 2026. If the fund’s investment in the shares of EfTEN Real Estate Fund AS were recognised on the basis of its net asset value, EfTEN United Property Fund would have earned 163 thousand euros of profit in August and the fund’s NAV would be 11.66 euros, increasing 0.6% over the month.

In August, the fund acquired a 5.9% holding in EfTEN Domina SIA, which owns the Domina shopping centre in Riga. The acquisition cost of the fund’s investment was 2,478 thousand euros, and in August the fund earned 31 thousand euros of profit from the change in the fair value of the holding.

In August, the fund also acquired an 80% holding in its subsidiary Invego Uus-Järveküla 2 OÜ, which is developing the expansion of the Uus-Järveküla residential district. The detailed plan for the expansion is in its final phase. The fund earns 10% annual interest income on the 700 thousand euro shareholder loan granted to the company at the end of July.

No new sales agreements were concluded in August in the development company Invego Uus-Järveküla OÜ, in which the fund holds an 80% stake. Three terraced-houses and two land plots remain unsold in the development project.

A more detailed overview of EfTEN United Property Fund’s portfolio can be found on the fund’s website: https://eftenunitedpropertyfund.ee/en/fund-results-2/

Kristjan Tamla
Managing Director
Phone: 655 9515

E-mail: kristjan.tamla@eften.ee

Attachment

• EUPF_dashboard_082026 (1)

VALLOUREC SECURES A MAJOR CONTRACT WITH SUBSEA7 FOR PETROBRAS’ SEPIA 2 OFFSHORE PROJECT IN BRAZIL

Meudon, on September 16, 2026 – Vallourec, a world leader in premium seamless tubular solutions, announces that it has been awarded a major contract by Subsea7 for the supply of carbon steel seamless line pipe and thermal insulation coating for the Sepia 2 project, developed by Petrobras in the pre-salt Santos Basin, offshore Brazil.

This award follows the EPCI (Engineering, Procurement, Construction and Installation) contract recently secured by Subsea7 from Petrobras for the Sepia 2 project. Vallourec has secured the project’s entire carbon steel line pipe and external coating supply scope through a single integrated offer.

Under this contract, Vallourec will supply approximately 130 kilometers of rigid risers and flowlines, representing more than 15,000 tons of sour service carbon steel line pipe. The pipes will be produced at Vallourec’s Jeceaba mill in Minas Gerais, Brazil, with the related thermal insulation coating applied at the Vallourec Coating Solutions plant in Serra, Espírito Santo.

The Sepia 2 project is located in ultra-deep waters of the Santos Basin, a pre-salt area approximately 280 kilometers from the Brazilian coast, and is developed by a consortium led by Petrobras. It comprises 15 wells, as well as an export pipeline connected to a new
Floating Production Storage and Offloading (FPSO) vessel, to be installed in a water depth of approximately 2,170 meters.

This success highlights Vallourec’s ability to meet the highly demanding thermal insulation requirements of the installation and operation phases in extreme deepwater conditions. Thanks to its advanced Syntactic Polypropylene solutions, Vallourec will stand alongside Subsea7 and Petrobras to meet these challenges throughout project execution.

Philippe Guillemot, Chairman of the Board of Directors and Chief Executive Officer of the Vallourec Group, commented: “This contract illustrates the strength of Vallourec’s integrated offering, combining premium seamless line pipe and advanced thermal insulation coating. It confirms our position as a partner of choice for the most demanding pre-salt developments and showcases the excellence of our fully integrated industrial footprint in Brazil, from our Jeceaba mill to our Serra coating plant. I thank Subsea7 and Petrobras for this new mark of confidence, which rewards the dedication of our teams.”

About Vallourec

Vallourec is a world leader in premium tubular solutions for the energy markets and for demanding industrial applications such as oil & gas wells in harsh environments, new generation power plants, challenging architectural projects, and high-performance mechanical equipment. Vallourec’s pioneering spirit and cutting-edge R&D open new technological frontiers. With close to 13,000 dedicated and passionate employees in more than 20 countries, Vallourec works hand- in-hand with its customers to offer more than just tubes: Vallourec delivers innovative, safe, competitive and smart tubular solutions, to make every project possible. Listed on Euronext in Paris (ISIN code: FR0013506730, Ticker VK), Vallourec is part of the CAC Mid 60, SBF 120 and Next 150 indices and is eligible for Deferred Settlement Service. In the United States, Vallourec has established a sponsored Level 1 American Depositary Receipt (ADR) program (ISIN code: US92023R4074, Ticker: VLOWY). Parity between ADR and a Vallourec ordinary share has been set at 5:1. 

For further information, please contact:

Investor relations:

Daniel Thomson
Tel: +44(0)75 91 83 74 05
daniel.thomson@vallourec.com

Individual shareholders:
Toll Free number (From France): 0 805 65 10 10 
actionnaires@vallourec.com

Press relations: Taddeo

Romain Grière
Tel: +33 (0) 7 86 53 17 29
Tel: + 1 718 421 8374
romain.griere@taddeo.fr

Nicolas Escoulan
Tel: +33 (0)6 42 19 14 74
nicolas.escoulan@taddeo.fr

Attachment

• PR_Sepia2_final

The Management Board of TextMagic AS (registry code: 16211377, hereinafter the Company) proposes this draft resolution of the shareholders with a view to adopting, without calling a meeting in accordance with Section 299¹ of the Commercial Code, the resolution of the shareholders of the Company on approval of the decrease of the voluntary reserve capital. 

In order to optimize costs, the Management Board of the Company has decided to arrange for the resolution to be adopted without convening a meeting and hence not to organise a general meeting of shareholders. 

Draft resolution:

Reduction of the voluntary reserve capital

Proposal of the Supervisory Board and the Management Board, and draft resolution.

1. To reduce the voluntary reserve capital of the Company by EUR 1,722,000 and to make a distribution to the shareholders in accordance with this resolution.

2. The distribution to be made as a result of the reduction of the Company’s voluntary reserve capital shall amount to EUR 0.20 per share (EUR 1,722,000 in total).

3. The remaining balance of the voluntary reserve capital after the distribution shall be EUR 25,988,000.

4. The distribution shall be allocated among all shareholders in proportion to the number of shares held by each shareholder in accordance with clause 4.12 of the Company’s articles of association.

The list of shareholders entitled to receive the distribution resulting from the reduction of the voluntary reserve capital shall be determined as at the close of the business day on 08.10.2026 (record date) in the Nasdaq CSD Estonian settlement system. Accordingly, the ex-date for the change of rights attached to the shares shall be 07.10.2026. The distribution shall be made to the shareholders no later than 14.10.2026.

Procedure and instructions for voting

A shareholder may review all documents related to the draft resolution on Company’s investors’ website https://investor.textmagic.com/ and at the Company’s location at A. H. Tammsaare tee 56, Tallinn, Harju County during business days from 09:00 to 17:00.

Questions regarding draft resolution, voting and other organizational issues are to be submitted to the Company’s e-mail address investor@textmagic.biz no later than by 25.09.2026 at 17:00.

The list of shareholders entitled to vote is fixed seven days before the end of the voting, i.e., on 23.09.2026 at the end of the business day of the settlement system of Nasdaq CSD Estonia. Shareholders may vote on draft resolutions only either by electronic means or by submitting a paper vote as follows:

1. the voting will be open from 10:00 on 16.09.2026 until 12:00 on 30.09.2026 (GMT +3);
2. a blank voting ballot is available at https://investor.textmagic.com/ where it can be filled in and the completed document can be downloaded for signing;
3. for electronic voting, a shareholder or its representative must fill in a blank voting ballot in accordance with the instructions therein, sign it electronically (using an ID card, digital ID or Mobile ID) and forward the electronically signed voting ballot to the e-mail address investor@textmagic.biz by the deadline specified in clause (i) above;
4. for paper voting, a shareholder or its legal or authorized representative must fill in a blank voting ballot in accordance with the instructions therein, sign it on paper and send the scanned voting ballot to the e-mail address investor@textmagic.biz and the original voting ballot to the Company’s head office at A. H. Tammsaare tee 56, 11316 Tallinn, Harju County, so that it arrives no later than at 12:00 (GMT+3) on 30.09.2026;
5. if a blank voting ballot is filled in by an authorized representative of a shareholder, the original of the relevant power of attorney in the form (in electronic form or on paper) and by the time specified in (iv) above must be delivered in addition to the voting ballot itself. A template of the power of attorney is available at https://investor.textmagic.com/;
6. if a blank voting ballot is filled in by a foreign legal entity, an extract of the registration entry of the relevant foreign legal entity, in the form (in electronic form or on paper) and by the time specified in (iv) above, showing the persons entitled to represent the foreign legal person must be delivered in addition to the voting ballot itself (and the power of attorney, if applicable).

Pursuant to Section 299¹(2) of the Commercial Code, if a shareholder does not state within the specified term whether the shareholder is for or against a resolution, the shareholder will be deemed to have voted against the resolution.

The Management Board will publish the voting results as a stock exchange announcement and on the Company’s website in accordance with Section 299¹(6) of the Commercial Code.
 

The following annexes are attached to this draft resolution:

Annex 1 – a blank voting ballot 
Annex 2 – a template of power of attorney

For more information, please contact:

Priit Vaikmaa
TextMagic AS CEO
investor@textmagic.biz

Attachments

• Annex 2 – Template of a power of attorney
• Annex 1 – Blank voting ballot

TGS’ presentation for the Pareto Securities Energy Conference 2026 can be downloaded from www.newsweb.no or TGS’ website www.tgs.com.

CEO Kristian Johansen will present today at 15:55 CEST.

For more information, visit TGS.com (http://www.tgs.com) or contact:

Bård Stenberg VP IR & Business Intelligence

Mobile: +47 992 45 235 investor@tgs.com

Attachment

• TGS Pareto Presentation 2026

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financing

SYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) — Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pivotal Phase 3 trial of Elate Ocular^® in moderate to severe dry eye disease (“DED”). The package comprises A$7.1 million (US$5.0 million) in firm commitments from strategic shareholders through a placement priced at A$0.48 per share, a 4.3% premium to the last closing price, and an A$3.75 million secured facility that pre-finances the Company’s FY2027 Research and Development Tax Incentive refund.

Highlights

• Strategic capital at a premium. A$7.1 million committed by strategic shareholders, extending a track record of raising capital at a premium.
• Funding to initiate the pivotal trial. CAMOMILE-2 is a single 475-patient Phase 3 trial that the U.S. Food and Drug Administration (FDA) has confirmed is sufficient to support a Biologics License Application (BLA). Initiation is targeted for the fourth quarter of 2026.
• A potential first-in-class biologic. Elate Ocular^® is a biologic derived from human platelet lysate. To the Company’s knowledge, no biologic therapy has been approved for the treatment of dry eye disease, and Elate Ocular^® has the potential to be the first. The program holds FDA Fast Track designation.
• Clear path to registration. Topline data from the pivotal trial are targeted for late calendar 2027. Subject to the trial meeting its co-primary sign and symptom endpoints, the Company intends to file a BLA with the FDA in 2028.

Karolis Rosickas, Chief Executive Officer of Cambium Bio, said:

“Our strategic shareholders have once again backed Cambium Bio at a premium to market, and that support now gives us the funding to start the pivotal trial of Elate Ocular^®. Dry eye disease still has no approved biologic therapy. With one pivotal trial agreed with the FDA, Fast Track designation and the funding in place to initiate that trial, our path is clear: topline data in late 2027 and a BLA filing in 2028.”

The placement is conditional on shareholder approval at the Company’s 2026 Annual General Meeting. Full details are in the Company’s ASX announcement dated 16 September 2026 at www.asx.com.au.

About Cambium Bio Limited

Cambium Bio Limited (ASX: CMB) is a Sydney-based clinical-stage regenerative medicine company developing biologics for ophthalmology and tissue repair from its proprietary human platelet lysate technology. Its lead product candidate, Elate Ocular^®, is being developed for moderate to severe dry eye disease.

Contact

Karolis Rosickas, Chief Executive Officer
info@cambium.bio